Skip to content
Acromegaly Update cover art

Ethan Weiss

Acromegaly Update

A Life Sciences and Science podcast

Good podcast? Give it some love!

About the show

Weekly digest of new research on acromegaly — trials, therapies, and clinical updates.

Newest episodes

Acromegaly Update — Monday November 16, 2026

7 min

Another incremental week for acromegaly research, led by evidence that upper-limb joint damage is nearly universal in patients and an early AI voice test for diagnosis, while rare disease industry news was dominated by deal-making (Lilly's up-to-$1.5B Calytrix buyout, argenx's Unnatural Products acquisition), a positive pivotal hepatitis delta readout from Vir, and Novo's sickle cell filing.

Acromegaly Update — Monday November 9, 2026

5 min

A quiet week for top-tier acromegaly papers, with a useful surgical-outcome predictor and a new treatment-landscape review, while rare disease industry news was dominated by setbacks: a failed Becker muscular dystrophy trial, deep Ultragenyx layoffs, and a new safety signal for Zolgensma.

Acromegaly Update — Monday November 2, 2026

4 min

A quiet week for acromegaly, with no top-tier-journal papers and only incremental observational work (tumor size drives headache; surgical remission isn't predicted by tumor subtype), while rare disease industry news was dominated by an FDA draft framework for "plug and play" gene therapies and a fresh $90M launch in Charcot-Marie-Tooth.

Similar podcasts

All episodes

Acromegaly Update — Monday November 16, 2026

7 min

Another incremental week for acromegaly research, led by evidence that upper-limb joint damage is nearly universal in patients and an early AI voice test for diagnosis, while rare disease industry news was dominated by deal-making (Lilly's up-to-$1.5B Calytrix buyout, argenx's Unnatural Products acquisition), a positive pivotal hepatitis delta readout from Vir, and Novo's sickle cell filing.

Acromegaly Update — Monday November 9, 2026

5 min

A quiet week for top-tier acromegaly papers, with a useful surgical-outcome predictor and a new treatment-landscape review, while rare disease industry news was dominated by setbacks: a failed Becker muscular dystrophy trial, deep Ultragenyx layoffs, and a new safety signal for Zolgensma.

Acromegaly Update — Monday November 2, 2026

4 min

A quiet week for acromegaly, with no top-tier-journal papers and only incremental observational work (tumor size drives headache; surgical remission isn't predicted by tumor subtype), while rare disease industry news was dominated by an FDA draft framework for "plug and play" gene therapies and a fresh $90M launch in Charcot-Marie-Tooth.

Acromegaly Update — Monday October 26, 2026

5 min

A thin top-tier week for acromegaly (one Pituitary paper plus a handful of solid next-tier studies, including a 2026 pipeline review), while rare disease news was dominated by positive Phase 3 readouts from Disc Medicine and Roivant, a second FDA look at Biohaven's ataxia drug, and early Huntington's data from Alnylam.

Acromegaly Update — Monday October 5, 2026

7 min

A thin week: no top-tier-journal acromegaly papers appeared, so Part A draws on the next tier (a radiomics model to predict somatostatin-analog response, a familial Carney-complex case, and bone proteomics), while the rare disease industry's big story is uniQure's four-year Huntington's gene therapy data, which showed a smaller, non-significant benefit and sent the stock down about 40%.

Acromegaly Update — Monday September 28, 2026

7 min

A quiet week for top-tier acromegaly literature (four papers, mostly real-world/consensus rather than trial data) paired with a livelier rare disease industry week — a first-ever positive pivotal trial in X-linked retinitis pigmentosa and a new FOP approval that goes head-to-head with Regeneron — while Marea's own MAR002 acromegaly program remains the clearest bridge between the two segments following its merger with Lisata.

Acromegaly Update — Monday September 21, 2026

7 min

This week's acromegaly literature centers on long-term disease burden — cardiovascular morbidity, musculoskeletal disease, and precision-medicine treatment selection — while the rare disease industry notched a landmark ultra-rare gene therapy approval, a $1.65B radiopharma merger, and a $123M bet on an oral thyroid eye disease pill.

Acromegaly Update — Tuesday September 15, 2026

7 min

It's a quiet week for acromegaly-specific research — just one review paper worth flagging — but rare disease industry news was busy, headlined by Scholar Rock's first-ever muscle-targeted SMA approval and a rough week for two RNA-based rare disease programs at Novartis.

Acromegaly Update — Monday September 7, 2026

7 min

It's a thin week for acromegaly-specific research — no top-tier-journal hits, so we're covering the best next-tier evidence on GH-axis physiology, octreotide drug delivery, and pituitary imaging AI — while rare disease industry news delivers a sharp one-two: Ionis just won the first-ever approval for Alexander disease, days after Ultragenyx's marquee Angelman syndrome drug flopped in Phase 3.

Acromegaly Update — Tuesday September 1, 2026

7 min

It's a quiet week for dedicated acromegaly research — no top-tier-journal hits, just a pasireotide cost-effectiveness review and a giant-adenoma case report — while the wider rare disease industry absorbed a surprise Phase 3 failure in the ATTR-CM heart drug market and a fresh round of White House drug-pricing deals touching major rare-disease manufacturers.

Acromegaly Update — Monday August 31, 2026

7 min

It's a quiet week for acromegaly-specific research — no top-tier trials, just a handful of diagnostic and mechanistic papers — while rare disease industry news brought two new FDA approvals (Priovant's Lisraya for dermatomyositis and Takeda/Protagonist's Mimrylo for polycythemia vera) that show regulators keep clearing novel mechanisms for small patient populations.

Acromegaly Update — Monday August 24, 2026

7 min

It was a quiet week for acromegaly-specific research — three observational studies refined how we monitor and support patients rather than changing treatment — while the wider rare disease industry saw two major FDA approvals and two sizable M&A deals land within days of each other.

Acromegaly Update — Monday August 17, 2026

7 min

It's an unusually rich week for acromegaly research — five new papers spanning a first-in-human antagonist trial and two large Swedish outcomes studies — while the rare disease industry saw a $1.3B rare-epilepsy buyout, a bankruptcy-auction gene therapy pickup, and a safety scare over a newly approved Prader-Willi drug.

Acromegaly Update — Monday August 10, 2026

7 min

It's a quiet week for acromegaly-specific trial data — the research side leans mechanistic and clinical-management, headlined by a novel long-acting GH receptor antagonist — while rare disease industry news brought a fresh Phase 2 win for Silence Therapeutics, an $800M Stargardt disease acquisition, a CRISPR safety insight from Intellia, and a Washington fight over whether orphan drugs get carved out of Medicare price pilots.

Acromegaly Update — Monday August 3, 2026

7 min

It's a quiet week for acromegaly-specific research — no trials, just incremental papers on AI-assisted detection, surgical outcomes, and pediatric gigantism — while the broader rare disease industry saw a gene-editing "gold rush" for a liver/lung disorder, a financing bet against two bigger rivals in Angelman syndrome, and a pulmonary hypertension partnership fall apart after a near-miss trial.

Acromegaly Update — Monday July 27, 2026

7 min

A trio of new Pituitary papers built out the real-world case for oral paltusotine in controlled acromegaly, while on the industry side a small rare-disease repurposing startup inked a licensing deal and orphan drugmakers pushed back on Medicare price-pilot exposure.

Acromegaly Update — Monday July 20, 2026

7 min

A quiet week for acromegaly research was anchored by a strong AI-diagnosis paper in JCEM, while rare disease headlines swung between a startup's ultrasound gene-therapy bombshell and a somber earnings-style readout on a rare endocrine disorder.

Acromegaly Update — Monday July 13, 2026

4 min

It was a quiet week for new acromegaly research, but the rare disease industry delivered its biggest story of the year — Vertex's $10 billion acquisition of Crinetics Pharmaceuticals, maker of the acromegaly drug Palsonify, directly linking this week's two segments.

Acromegaly Update — Monday July 6, 2026

7 min

It's a thin week for acromegaly-specific research — just one mechanistic study on tumor biology — but rare disease dealmaking was busy, headlined by Ipsen's ~$800M bet on a kidney-transplant antiviral and an FDA age expansion for Vertex's CRISPR therapy Casgevy.

Acromegaly Update — Monday June 29, 2026

7 min

Paltusotine's four-year open-label data confirm durable oral control of acromegaly in patients switched from injections, while the rare disease industry absorbs a landmark Sangamo bankruptcy, a well-funded gene-editing entrant in AATD, and a new build-to-buy cardiomyopathy venture from Merck KGaA.

Acromegaly Update — Monday June 22, 2026

12 min

A rich week in acromegaly research — new data on renal complications, a precision medicine framework, a high-risk co-secreting tumor phenotype, and cancer risk analyses — while the rare disease industry continues to see a wave of FDA regulatory reversals benefiting gene therapy developers.

Acromegaly Update — Monday June 15, 2026

7 min

Surgical technique innovation and a JCEM editorial from two giants of the field reshape how we think about curing GH-secreting tumors and managing cancer risk in acromegaly, while the rare disease sector sees a burst of late-stage deal-making and platform financing that signals strong investor conviction in gene-silencing technologies.

Acromegaly Update — Monday June 8, 2026

13 min

A landmark JCEM special issue lands this week with five major reviews and original studies that collectively reset the clinical playbook for acromegaly — from emerging oral therapies to the underappreciated mortality burden — while in the rare disease industry, Alnylam bets $2 billion on AI-designed RNA medicines, a controversial FDA voucher program faces calls for reform, and a new market forecast projects orphan drug sales above $400 billion by 2032.

Acromegaly Update — Monday June 1, 2026

7 min

New Pituitary research this week highlights the cardiac and bone risks that persist even in treated acromegaly patients, while the rare disease industry grapples with a mixed regulatory environment — one notable ASCO data release and continued fallout from FDA leadership turnover.

Acromegaly Update — Monday May 25, 2026

7 min

A network meta-analysis confirms that injectable somatostatin receptor ligands remain first-line in acromegaly, while new clinical data on paltusotine and pasireotide, plus rare disease industry news including BioMarin and Intellia, shape the week.

Acromegaly Update — Monday May 18, 2026

7 min

New proteomic biomarkers could sharpen acromegaly diagnosis beyond GH/IGF-1, while the rare disease industry sees a wave of FDA decisions and high-stakes M&A activity.

Acromegaly Update — Monday May 11, 2026

7 min

Acromegaly research this week centered on the long-term pharmacology of established therapies and clinical management updates, while the rare disease industry absorbed significant regulatory and pipeline news.

Acromegaly Update — Thursday May 7, 2026

7 min

This week's literature brings a long-term safety confirmation for pegvisomant monotherapy, a head-to-head comparison of first-generation somatostatin analogs using a validated composite score, and new evidence linking acromegaly to hepatic steatosis — alongside cost-effectiveness data for pasireotide and updated pituitary tumor pathology tools.

Acromegaly Update — Monday May 4, 2026

7 min

Two important consensus-level papers from late April 2026 sharpen the standards for acromegaly diagnosis and comorbidity management, incorporating AI-assisted screening, ultrasensitive GH assays, and updated international expert guidance.

Acromegaly Update — Tuesday April 28, 2026

7 min

This week's acromegaly literature is headlined by a landmark cardiovascular disease review in Endocrine Reviews and a cluster of high-yield JCEM papers covering biomarker-guided therapy, standardized pituitary imaging, patient-reported quality of life, and histological predictors of surgical remission.

–

0 ratings from members

5
4
3
2
1

Rate this podcast

Log in to rate and review the shows you listen to.

No reviews yet — be the first member to rate "Acromegaly Update".

This podcast, its content and its artwork are not owned by, affiliated with, or endorsed by Castquire.

Keep listening

Discover more podcasts like this.

Up next

  1. Nothing queued. Use + Queue on any episode to line it up.

0:00 0:00